Glancy
Binkow & Goldberg LLP reminds investors of STAAR
Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA) that
purchasers of STAAR securities between February 27, 2013 and June 30,
2014, inclusive (the “Class Period”), have until September 8, 2014, to
file a motion to be appointed as lead plaintiff in the shareholder
lawsuit.
STAAR, together with its subsidiaries, designs, develops, manufactures
and sells implantable lenses for the eye and delivery systems to deliver
lenses into the eye. The Complaint
alleges that STAAR’s Monrovia, California, manufacturing facility lacked
adequate methodologies and facilities for the manufacture, packing,
storage and installation of the Company’s implantable lenses, lacked
adequate procedures for documenting complaints, sterility testing and
maintaining required records, and as a result was not in conformity with
current good manufacturing practice requirements at all relevant times.
On June 30, 2014, the U.S. Food and Drug Administration released a
Warning Letter, dated May 21, 2014, concerning an inspection of STAAR’s
Monrovia facility from February 10, 2014 to March 21, 2014. The FDA
letter noted several regulatory violations at the facility and stated
that, among other things, “the methods used in, or the facilities or
controls used for” manufacture, packing, storage or installation of the
Company’s implantable lenses are “not in conformity with the current
good manufacturing practice requirements.” The FDA further advised STAAR
that “failure to promptly correct these violations may result in
regulatory action being initiated by the FDA without further notice.”
If you are a member of the Class described above, you may move the Court
no later than September 8, 2014, to serve as lead plaintiff; however,
you must meet certain legal requirements. To be a member of the Class,
you need not take any action at this time; you may retain counsel of
your choice or take no action and remain an absent member of the Class.
If you wish to learn more about this action or have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Casey Sadler, Esquire, of Glancy Binkow &
Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, by toll-free telephone at (888) 773-9224 or by
telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2014